QTRX - Quanterix Corp Stock Price, Fair Value and News

16.04USD-0.06 (-0.37%)Market Closed

Market Summary

USD16.04-0.06

Market Closed

-0.37%

QTRX Stock Price

View Fullscreen

QTRX RSI Chart

QTRX Valuation

Market Cap

610.5M

Price/Earnings (Trailing)

-18.88

Price/Sales (Trailing)

4.99

EV/EBITDA

-46.34

Price/Free Cashflow

-26.91

QTRX Price/Sales (Trailing)

QTRX Profitability

Operating Margin

57.73%

EBT Margin

-25.84%

Return on Equity

-9.32%

Return on Assets

-7.61%

Free Cashflow Yield

-3.72%

QTRX Fundamentals

QTRX Revenue

Revenue (TTM)

122.4M

Rev. Growth (Yr)

22.17%

Rev. Growth (Qtr)

0.69%

QTRX Earnings

Earnings (TTM)

-32.3M

Earnings Growth (Yr)

33.22%

Earnings Growth (Qtr)

-59.95%

Breaking Down QTRX Revenue

Last 7 days

1.8%

Last 30 days

-28.6%

Last 90 days

-31.4%

Trailing 12 Months

37.5%

How does QTRX drawdown profile look like?

QTRX Financial Health

Current Ratio

9.84

Debt/Equity

0.01

Debt/Cashflow

-9.91

QTRX Investor Care

Shares Dilution (1Y)

2.19%

Diluted EPS (TTM)

-0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	104.4M	112.0M	116.6M	122.4M
2022	112.9M	111.0M	110.0M	105.5M
2021	97.9M	110.1M	106.4M	110.6M
2020	60.1M	59.7M	76.2M	86.4M
2019	42.4M	47.3M	51.7M	56.7M
2018	25.1M	28.5M	33.3M	37.6M
2017	18.9M	20.2M	21.6M	22.9M
2016	0	0	0	17.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Quanterix Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	toloue masoud	sold (taxes)	-19,208	17.15	-1,120	president & ceo
Apr 01, 2024	olson laurie j	acquired	12,860	12.86	1,000	-
Apr 01, 2024	meister paul m	acquired	14,981	23.78	630	-
Apr 01, 2024	hlavinka sarah e.	acquired	14,981	23.78	630	-
Apr 01, 2024	olson laurie j	sold	-23,500	23.5	-1,000	-
Apr 01, 2024	donnelly william p	acquired	12,484	23.78	525	-
Mar 31, 2024	toloue masoud	sold (taxes)	-26,387	23.56	-1,120	president & ceo
Mar 15, 2024	toloue masoud	sold (taxes)	-29,736	26.55	-1,120	president & ceo
Feb 29, 2024	toloue masoud	sold (taxes)	-17,347	23.96	-724	president & ceo
Feb 14, 2024	olson laurie j	sold	-36,525	24.35	-1,500	-

Which funds bought or sold QTRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-64.83	-64,000	28,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	3,560	486,625	-%
Apr 22, 2024	Ashton Thomas Private Wealth, LLC	new	-	473,556	473,556	0.03%
Apr 19, 2024	VALLEY NATIONAL ADVISERS INC	sold off	-100	-1,000	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	22.28	15,426	302,605	-%
Apr 17, 2024	Clarius Group, LLC	unchanged	-	-234,586	1,462,130	0.10%
Apr 16, 2024	Pinnacle Bancorp, Inc.	unchanged	-	-1,966	12,251	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	unchanged	-	-158	990	-%
Apr 05, 2024	CWM, LLC	reduced	-22.77	-1,608,000	3,199,000	0.02%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	93.64	190,626	475,700	-%

Are Funds Buying or Selling QTRX?

Are funds buying QTRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own QTRX

No. of Funds

Unveiling Quanterix Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	pura vida investments, llc	2.14%	811,332	SC 13G/A
Feb 14, 2024	pura vida investments, llc	5.22%	1,935,441	SC 13G/A
Feb 14, 2024	camber capital management lp	0%	2,013	SC 13G/A
Feb 13, 2024	vanguard group inc	5.43%	2,055,033	SC 13G
Jan 29, 2024	millennium management llc	5.5%	2,082,903	SC 13G/A
Jan 25, 2024	blackrock inc.	8.4%	3,190,625	SC 13G/A
Sep 29, 2023	millennium management llc	5.3%	1,985,682	SC 13G
Feb 23, 2023	pura vida investments, llc	5.62%	2,080,641	SC 13G/A
Feb 14, 2023	gilder gagnon howe & co llc	2.5%	943,421	SC 13G/A
Feb 14, 2023	camber capital management lp	9.24%	2,013	SC 13G/A

Recent SEC filings of Quanterix Corp

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A
Apr 12, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Quanterix Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.82%	-2.78%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-3.26%	-10.41%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-1.72%	-10.74%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.03%	-9.90%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	0.44%	-12.46%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-2.07%	18.57%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.49%	-36.41%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.85%	-24.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-3.04%	14.62%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-3.54%	-1.62%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.37%	-14.88%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	3.23%	-3.00%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	11.39%	-31.43%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	18.11%	-48.10%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-12.07%	240.00%	-0.33	1.07	5.77%	8.23%

Quanterix Corp News

Latest updates

Quanterix Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	0.7%	31,549,000	31,334,000	31,029,000	28,456,000	25,824,000	26,646,000	23,500,000	29,552,000	30,287,000	27,689,000	25,371,000	27,209,000	26,131,000	31,389,000	13,130,000	15,727,000	15,917,000	14,944,000	13,536,000	12,337,000	10,877,000
Cost Of Revenue	8.8%	14,750,000	13,551,000	11,891,000	11,530,000	13,232,000	15,702,000	14,789,000	14,993,000	14,026,000	12,445,000	11,497,000	10,860,000	11,081,000	10,283,000	7,917,000	8,914,000	9,052,000	7,911,000	6,605,000	6,330,000	5,669,000
Gross Profit	-5.5%	16,799,000	17,783,000	19,138,000	16,926,000	12,592,000	10,944,000	8,711,000	14,559,000	16,261,000	15,244,000	13,874,000	16,349,000	15,050,000	21,106,000	5,213,000	6,813,000	6,865,000	7,033,000	6,931,000	6,007,000	5,208,000
Operating Expenses	7.0%	33,749,000	31,553,000	28,699,000	26,346,000	34,547,000	47,547,000	33,670,000	32,746,000	36,157,000	30,477,000	27,542,000	26,138,000	24,983,000	18,828,000	17,414,000	18,541,000	18,351,000	17,276,000	17,445,000	15,364,000	14,622,000
S&GA Expenses	2.4%	24,172,000	23,595,000	21,591,000	20,883,000	19,272,000	19,966,000	27,045,000	25,712,000	28,423,000	23,670,000	20,788,000	19,455,000	18,766,000	13,451,000	13,102,000	14,273,000	13,953,000	13,352,000	13,429,000	11,512,000	10,577,000
R&D Expenses	-2.9%	6,991,000	7,200,000	5,946,000	4,720,000	5,600,000	6,631,000	6,625,000	7,034,000	7,734,000	6,807,000	6,754,000	6,683,000	6,217,000	5,377,000	4,312,000	4,268,000	4,398,000	3,924,000	4,016,000	3,852,000	4,045,000
EBITDA Margin	49.0%	-0.08	-0.15	-0.43	-0.67	-0.82	-0.82	-0.66	-0.54	-0.48	-0.41	-0.24	-0.27	-	-	-	-	-	-	-	-	-
Interest Expenses	3.2%	4,319,000	4,185,000	3,886,000	3,449,000	2,815,000	1,712,000	552,000	52,000	15,000	-90,000	-165,000	-163,000	-166,000	-160,000	-108,000	161,000	282,000	282,000	42,000	21,000	24,000
Income Taxes	-20.7%	161,000	203,000	235,000	100,000	55,500	72,000	137,000	-200,000	-68,000	33,000	41,000	-42,000	-123,000	-111,000	-18,000	-124,000	-107,000	-125,000	23,000	22,000	25,000
Earnings Before Taxes	-62.4%	-12,268,000	-7,555,000	-5,829,000	-5,963,000	-18,526,000	-34,992,000	-24,765,000	-18,352,000	-20,094,000	-15,628,000	-11,856,000	-10,146,000	-9,944,000	2,092,000	-12,320,000	-11,734,000	-11,065,000	-9,995,000	-10,540,000	-9,383,000	-9,309,000
EBT Margin	20.4%	-0.26	-0.32	-0.58	-0.81	-0.92	-0.89	-0.71	-0.58	-0.52	-0.45	-0.27	-0.31	-	-	-	-	-	-	-	-	-
Net Income	-60.0%	-12,409,000	-7,758,000	-6,064,000	-6,103,000	-18,581,000	-35,064,000	-24,902,000	-18,153,000	-20,026,000	-15,661,000	-11,897,000	-10,104,000	-9,821,000	2,203,000	-12,302,000	-11,610,000	-10,958,000	-9,870,000	-10,563,000	-9,405,000	-9,334,000
Net Income Margin	20.0%	-0.26	-0.33	-0.59	-0.81	-0.92	-0.89	-0.71	-0.58	-0.52	-0.45	-0.27	-0.31	-	-	-	-	-	-	-	-	-
Free Cashflow	-69.5%	-8,200,000	-4,837,000	-15,000	-9,638,000	-5,685,000	-18,224,000	-13,000,000	-23,089,000	-12,745,000	-17,601,000	-17,009,000	-14,168,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.9%	425	429	429	427	434	447	489	505	502	511	528	533	271	264	163	170	170	176	109	65.00	68.00
Current Assets	-0.7%	378	381	379	376	381	387	413	434	449	459	476	482	220	215	114	123	133	139	92.00	52.00	59.00
Cash Equivalents	-13.3%	174	201	330	329	339	344	364	374	399	411	431	443	183	173	89.00	96.00	110	113	72.00	34.00	45.00
Inventory	12.1%	22.00	20.00	18.00	17.00	17.00	18.00	22.00	23.00	22.00	23.00	21.00	17.00	15.00	13.00	14.00	11.00	10.00	11.00	9.00	8.00	6.00
Net PPE	2.3%	18.00	18.00	18.00	19.00	20.00	21.00	22.00	20.00	18.00	16.00	16.00	14.00	14.00	13.00	12.00	12.00	12.00	12.00	12.00	9.00	3.00
Goodwill	-	-	-	-	-	-	-	9.00	9.00	10.00	10.00	10.00	10.00	10.00	10.00	9.00	9.00	9.00	9.00	1.00	1.00	1.00
Liabilities	3.2%	78.00	76.00	74.00	70.00	75.00	74.00	-	-	61.00	55.00	62.00	61.00	65.00	55.00	52.00	51.00	41.00	39.00	35.00	31.00	27.00
Current Liabilities	9.4%	38.00	35.00	32.00	27.00	31.00	29.00	37.00	32.00	37.00	31.00	38.00	36.00	40.00	28.00	19.00	18.00	20.00	18.00	17.00	17.00	18.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	2.00	8.00	8.00	8.00	6.00	-	-	0.00	0.00	0.00	0.00	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Shareholder's Equity	-1.8%	347	353	355	357	359	373	405	426	441	456	466	471	206	209	111	119	129	136	75.00	34.00	41.00
Retained Earnings	-2.9%	-434	-422	-414	-408	-402	-383	-348	-323	-305	-285	-269	-257	-247	-237	-240	-227	-216	-205	-195	-184	-175
Additional Paid-In Capital	0.6%	783	779	772	768	764	759	756	751	746	740	734	728	451	446	351	348	345	343	270	219	217
Shares Outstanding	0.5%	38.00	38.00	38.00	37.00	37.00	37.00	37.00	37.00	36.00	37.00	35.00	34.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	796	-	-	-	558	-	-	-	2,100	-	-	-	234	-	-	-	547	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-47.8%	-5,984	-4,049	633	-9,502	-4,090	-14,547	-7,940	-21,695	-10,292	-13,777	-9,749	-14,089	4,654	-7,419	-7,421	-13,179	-4,535	-8,832	-7,468	-5,352	-8,108
Share Based Compensation	-0.4%	4,326	4,343	4,193	3,902	3,663	2,766	5,186	3,827	4,931	4,008	3,650	3,386	3,129	2,360	2,501	2,109	1,675	1,828	1,601	1,284	1,491
Cashflow From Investing	82.8%	-21,629	-125,988	-648	-136	-1,595	-3,677	-5,060	-874	-2,194	-2,015	-4,564	2,435	1,523	-788	-935	-426	-544	-15,002	-3,913	-5,917	-107
Cashflow From Financing	-88.8%	201	1,800	139	551	714	407	211	979	-851	-4,060	2,393	273,313	2,076	92,684	615	861	724	65,201	49,441	831	1,221

QTRX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 122,368	$ 105,522	$ 110,556
Costs of goods sold and services:
Total costs of goods sold and services	51,722	58,716	48,828
Gross profit	70,646	46,806	61,728
Operating expenses:
Research and development	24,857	25,890	27,978
Selling, general and administrative	90,241	91,995	92,336
Other lease costs	3,712	1,278
Impairment and restructuring	1,537	29,347	0
Total operating expenses	120,347	148,510	120,314
Loss from operations	(49,701)	(101,704)	(58,586)
Interest income (expense), net	15,839	5,131	(403)
Other income (expense), net	2,247	(62)	1,265
Loss before income taxes	(31,615)	(96,635)	(57,724)
Income tax (expense) benefit	(719)	(65)	36
Net loss	$ (32,334)	$ (96,700)	$ (57,688)
Net loss per common share, basic (in dollars per share)	$ (0.86)	$ (2.61)	$ (1.60)
Net loss per common share, diluted (in dollars per share)	$ (0.86)	$ (2.61)	$ (1.60)
Weighted-average common shares outstanding, basic (in shares)	37,594	36,991	35,997
Weighted-average common shares outstanding, diluted (in shares)	37,594	36,991	35,997
Product revenue
Revenues:
Total revenues	$ 79,460	$ 69,808	$ 81,062
Costs of goods sold and services:
Total costs of goods sold and services	32,636	40,809	34,149
Service revenue
Revenues:
Total revenues		34,495
Service and other revenue.
Revenues:
Total revenues	40,299	34,495	23,629
Costs of goods sold and services:
Total costs of goods sold and services	19,086	17,907	14,679
Collaboration and license revenue
Revenues:
Total revenues	1,380	649	648
Grant revenue
Revenues:
Total revenues	$ 1,229	$ 570	$ 5,217

QTRX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 174,422	$ 338,740
Marketable securities	146,902	0
Accounts receivable, net of allowance for expected credit losses	25,414	19,017
Inventory	22,365	16,786
Prepaid expenses and other current assets	9,291	6,860
Total current assets	378,394	381,403
Restricted cash	2,604	2,597
Property and equipment, net	17,926	20,162
Intangible assets, net	6,034	7,516
Operating lease right-of-use assets	18,251	21,223
Other non-current assets	1,802	1,298
Total assets	425,011	434,199
Current liabilities:
Accounts payable	5,048	3,836
Accrued compensation and benefits	13,659	10,658
Accrued expenses and other current liabilities	6,041	5,133
Deferred revenue	9,468	8,644
Short-term operating lease liabilities	4,241	2,687
Total current liabilities	38,457	30,958
Deferred revenue, net of current portion	1,227	1,415
Non-current operating lease liabilities	37,223	41,417
Other non-current liabilities	1,177	1,469
Total liabilities	78,084	75,259
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.001 par value, per share: Authorized: XXX,XXX; issued and outstanding: 38,014 and 37,280 shares at December 31, 2023 and 2022, respectively	38	37
Additional paid-in capital	783,142	763,688
Accumulated other comprehensive loss	(1,757)	(2,623)
Accumulated deficit	(434,496)	(402,162)
Total stockholders' equity	346,927	358,940
Total liabilities and stockholders' equity	$ 425,011	$ 434,199

About Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

CEO	Dr. Masoud Toloue Ph.D.
WEBSITE	quanterix.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	3200

Quanterix Corp Frequently Asked Questions

What is the ticker symbol for Quanterix Corp? What does QTRX stand for in stocks?

QTRX is the stock ticker symbol of Quanterix Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Quanterix Corp (QTRX)?

As of Wed Apr 24 2024, market cap of Quanterix Corp is 610.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QTRX stock?

You can check QTRX's fair value in chart for subscribers.

What is the fair value of QTRX stock?

You can check QTRX's fair value in chart for subscribers. The fair value of Quanterix Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Quanterix Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for QTRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Quanterix Corp a good stock to buy?

The fair value guage provides a quick view whether QTRX is over valued or under valued. Whether Quanterix Corp is cheap or expensive depends on the assumptions which impact Quanterix Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QTRX.

What is Quanterix Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, QTRX's PE ratio (Price to Earnings) is -18.88 and Price to Sales (PS) ratio is 4.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. QTRX PE ratio will change depending on the future growth rate expectations of investors.